BlackRock’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

BlackRock’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-88,635	Closed	-$17.3K	–	5434
2023 Q4	$17.3K	Sell	88,635 -390	-0.4%	-$85	﹤0.01%	5101
2023 Q3	$32.6K	Sell	89,025 -1,365	-2%	-$921	﹤0.01%	5079
2023 Q2	$97.6K	Buy	90,390 +9,223	+11%	+$8.92K	﹤0.01%	4923
2023 Q1	$56.8K	Buy	81,167 +798	+1%	+$937	﹤0.01%	5095
2022 Q4	$88.8K	Buy	80,369 +1,645	+2%	+$2.43K	﹤0.01%	5080
2022 Q3	$139K	Buy	78,724 +2,776	+4%	+$5.06K	﹤0.01%	5079
2022 Q2	$118K	Buy	+75,948	New	+$127K	﹤0.01%	5194

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

BlackRock's BTTX Position: Q1 2024 in Review

BlackRock sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 88,635 shares — an estimated $17.3K sold.

BlackRock first reported a position in BTTX in Q2 2022 and held it in 7 quarters. The position peaked at $139K in Q3 2022. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

BlackRock reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
BlackRock sold 88,635 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $17.3K.
BlackRock first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
BlackRock's Better Therapeutics, Inc. Common Stock position peaked at $139K in Q3 2022.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.